pharmaphorum December 9, 2024
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not create competition issues and can go ahead, according to the European Commission.
Novo Holdings – the parent company of Danish pharma group Novo Nordisk – said that it now expects the takeover to finalise before the end of the year. Catalent stockholders voted to approve it in May.
The transaction – first announced in February – would see Novo Nordisk subsequently pay $11 billion to take control of three of Catalent’s fill-and-finish facilities, which would allow it to ramp up production capacity for key medicines, including drugs for diabetes and obesity.
“The proposed merger would not raise competition concerns on any of the markets...
Today's Sponsors
Today's Sponsor